Pirfenidone 267 MG [Esbriet]

DRUG2 trials

Sponsors

Stanford University, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Conditions

Bronchiolitis ObliteransGraft Vs Host DiseaseIdiopathic Subglottic StenosisSubglottic Stenosis (SGS)

Phase 1

The Safety and Tolerability of Pirfenidone for BOS After HCT

CompletedNCT03315741

Stanford UniversityBronchiolitis Obliterans, Graft Vs Host Disease

Start: 2018-03-01End: 2022-04-27Updated: 2022-06-13

A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis

Not yet recruitingNCT07654517

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sIdiopathic Subglottic Stenosis, Subglottic Stenosis (SGS)

Start: 2026-12-01End: 2029-12-01Target: 40Updated: 2026-06-17

Related Papers

Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease.

2025-10-011 citations

The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.

2022-05-3121 citations